• Explore /
  • Poster
  • / Safety and preliminary efficacy of intrathecal (IT) and intravenous (IV) nivolumab (N) for patients (pts) with leptomeningeal disease (LMD).

Safety and preliminary efficacy of intrathecal (IT) and intravenous (IV) nivolumab (N) for patients (pts) with leptomeningeal disease (LMD).

Abstract Poster

Authors

null

Isabella Claudia Glitza

MD Anderson Cancer Center, Houston, TX

Isabella Claudia Glitza , Ida John , Suzanne Phillips , Lauren See , Roland L. Bassett Jr., Ruitao Lin , Michelle L. Rohlfs , Jessie Richard , Masood Iqbal , Tarin Hennegan , Ian E. McCutcheon , Sherise D. Ferguson , Golnaz Morad , Barbara Jane O'Brien , Sudhakar Tummala , Nandita Guha- Thakurta , Matthew Debnam , Hussein A. Tawbi , Elizabeth M. Burton , Michael A. Davies

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT03025256

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 9554)

DOI

10.1200/JCO.2023.41.16_suppl.9554

Abstract #

9554

Poster Bd #

317

Abstract Disclosures

Similar Posters

First Author: Ida John

First Author: Golnaz Morad

First Author: Vincent Law

First Author: Bartosz Chmielowski